Login to Your Account



Mast Flags Offering's $22.9M for Sickle Cell Phase III Trial

By Randy Osborne
Staff Writer

Monday, June 17, 2013

Mast Therapeutics Inc.'s $22.9 million from a public offering will fund the second Phase III trial with the sickle cell disease candidate MST-188, a purified form of a nonionic, triblock copolymer (poloxamer 188) that was first developed for the treatment of heart attacks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription